|
Sign In to gain access to subscriptions and/or personal tools.
|
Controversies in meta-analysis: the case of the trials of serum cholesterol reduction
SG Thompson
London School of Hygiene and Tropical Medicine, London
There has recently been disagreement in the literature on the results and interpretation of meta-analyses of the trials of serum cholesterol reduction, both in terms of the quantification of the effect on ischaemic heart disease and as regards the evidence of any adverse effect on other causes of death. This paper describes statistical aspects of a recent meta-analysis of these trials, and draws some more general conclusions about the methods used in meta-analysis. Tests of an overall null hypothesis are shown to have a basis clearly distinct from the more extensive assumptions needed to provide an overall estimate of effect. The fixed effect approach to estimation relies on the implausible assumption of homogeneity of treatment effects across the trials, and is therefore likely to yield confidence intervals which are too narrow and conclusions which are too dogmatic. However the conventional random effects method relies on its own set of unrealistic assumptions, and cannot be regarded as a robust solution to the problem of statistical heterogeneity. The random effects method is more usefully regarded as a type of sensitivity analysis in which the weights allocated to each study in estimating the overall effect are modified. However, rather than using a statistical model for the 'unexplained' heterogeneity, greater insight and scientific understanding of the results of a set of trials may be obtained by a careful exploration of potential sources of heterogeneity. In the context of the cholesterol trials, the heterogeneity according to the extent and duration of cholesterol reduction are of prime concern and are investigated using logistic regression. It is concluded that the long-term benefits of serum cholesterol reduction on the risk of heart disease have been seriously underestimated in some previous meta-analyses, while the evidence for adverse effects on other causes of death have been misleadingly exaggerated.
Statistical Methods in Medical Research, Vol. 2, No. 2,
173-192 (1993)
DOI: 10.1177/096228029300200205

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. R. Crouse III, R. P. Byington, H. M. Hoen, and C. D. Furberg
Reductase Inhibitor Monotherapy and Stroke Prevention
Arch Intern Med,
June 23, 1997;
157(12):
1305 - 1310.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Keyserling, A. S. Ammerman, C. E. Davis, M. C. Mok, J. Garrett, and R. Simpson Jr
A Randomized Controlled Trial of a Physician-Directed Treatment Program for Low-Income Patients With High Blood Cholesterol: The Southeast Cholesterol Project
Arch Fam Med,
March 1, 1997;
6(2):
135 - 145.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Cappelleri, J. P. A. loannidis, C. H. Schmid, S. D. de Ferranti, M. Aubert, T. C. Chalmers, and J. Lau
Large Trials vs Meta-analysis of Smaller Trials: How Do Their Results Compare?
JAMA,
October 23, 1996;
276(16):
1332 - 1338.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. T. Jeng, J. R. Scott, and L. F. Burmeister
A Comparison of Meta-analytic Results Using Literature vs Individual Patient Data: Paternal Cell Immunization for Recurrent Miscarriage
JAMA,
September 13, 1995;
274(10):
830 - 836.
[Abstract]
[PDF]
|
 |
|
|
|